| Backer MV, Gaynutdinov TI, Gorshkova II, Crouch RJ, Hu T, Aloise R, Arab M, Przekop K, Backer JM
					(2003)
					J Controlled Release,
					89,
					499-511 | 
			
		
			
			    
				| Drug Studies | 
			
			
			    
				| None | 
			
			
			    
				| Protein recombinantly expressed as and refolded from inclusion bodies. | 
			
		
			
			    
				| Escherichia coli | 
			
			
			    
				| BL21(DE3) | 
			
			
			    
				| 37.0 | 
			
			
			    
				| 2 | 
			
			
			    
				| pET29a(+) | 
			
			
			    
				| Cells were grown in Circle Grow medium (Q-Biogen), expression was induced with 1mM IPTG when OD600 reached 0.5-0.7. Cells were grown for a further 2h at 37degC then harvested by centrifugation (15min x 5000g).  | 
			
			
			
			    
				| IPTG | 
			
			
			    
				| OD 600 =
					0.5-0.7 | 
			
		
			
			    
				| Sonication | 
			
			
			    
				| None | 
			
			
			    
				| None | 
			
	
			
			    
				| insoluble | 
			
																																																																																																												
			
			
			
			    
			
			
			    
				| Dialysis | 
			
	
			
			    
				| BugBuster (Novagen)/CelLytic B (Sigma), HisBind buffer (Novagen) | 
			
			
			    
				| 20mM TrisHCl, 100mM NaCl, 8M Urea pH 8.0 | 
			
			
			    
				| 1:20mM TrisHCl 2M Urea, 1mM glutathione, 0.4mM oxidized glutathione, 0.5M arginine, pH 8.0/2: 20mM TrisHCl pH 8.0 | 
			
			
			    
				| None | 
			
			
			    
				| no tag | 
			
			
			    
				| 8.0 | 
			
			
			    
				| 25.0 | 
			
			
			    
				 | 
			
			
			    
				 | 
			
			
			    
				| GSH/GSSG | 
			
			
			    
				| 1mM/0.4mM,1mM/0.4mM | 
			
			
			    
				| The cells were lysed using BugBuster reagent (Novagen) according to the instructions of the manufacturer. The inclusion bodies were were centrifuged and washed with BugBuster reagent, followed by CelLytic B reagent (Sigma) diluted 1:10 with water, and then finally 1x HisBind buffer (Novagen). The inclusion bodies were solubilized by sonication in solubilization buffer. The protein was then refolded by a 2-step dialysis process, firstly for 20h against 20 volumes of refolding buffer 1, then for 24h against 100 volumes of refolding buffer 2.
 | 
			
			
			    
				| Enzyme activity | 
			
			
			    
				| None | 
			
			
			    
				| None,L-Arginine | 
			
			
			    
				| 0.5M | 
			
						
			
			    
				 | 
			
			
			    
				| >95% | 
			
			
			    
				| Hu-VEGF  - same protocol as for VEGF, see separate  record no.1508
Other constructs also purified:
HuS (aa.18-125 or 18-127) - see separate protocols, records no.1507, 7k9h3
 |